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A b s t r a c t  
Simvastatin (SMV) are specific competitive inhibitors which are widely used to lower 
cholesterol for the treatment of hyperlipidemia and arteriosclerosis. They have shown to 
modulate bone formation by increasing the expression of bone morphogenetic protein-2, 
inflammation, and angiogenesis,3 thus providing a new direction in the field of periodontal 
therapy. The aim of this randomized trial was to assess the clinical and radiographic effects 
of 1.2% Simvastatin  gel as an adjunct to scaling and root planing in the treatment of chronic 
periodontitis. The IL-6 level in the sulcular epithelium was also evaluated before and after 
treatment with 1.2% simvastatin. 60 sites were selected with minimum one intrabony defect 
and probing pocket depth of >5mm and were divided into 2 groups; 30 sites were treated 
with SRP and placebo (Group A) and 30 sites were treated with SRP along with Simvastatin 
(SMV) (group B). Clinical parameters recorded at baseline before SRP and at 60th, 90th and 
180th day; included plaque index (PI), modified sulcus bleeding index (mSBI), probing depth 
(PD), and clinical attachment level (CAL). Radiologic assessment of intrabony defect (IBD) fill 
was done at baseline and after 6 months using computer-aided software. Interleukin-6-
mRNA (IL-6-mRNA) levels in sulcular epithelium was analysed for Group B at baseline and 3 
months after the drug application. Both therapies resulted in significant improvements in the 
parameters however SRP along with simvastatin showed statistically significant decrease in 
PI, mSBI and PD and gain in CAL at 6 months. In Group B, there was greater decrease in 
mean IBD as compared to Group A. At the molecular level the simvastatin group showed a 
significant decrease in IL-6-mRNA levels. The statistically significant improvement in clinical 
and hard tissue parameters at sites treated with SRP plus locally delivered SMV as well as 
its potency in reducing IL-6-mRNA levels proved the efficacy of  the drug as a local drug 
delivery system in the treatment of chronic periodontitis not only in clinical but as well as in 
molecular level. 
Keywords: local drug delivery, chronic periodontitis, simvastatin, interleukin-6, intrabony 
defects 
Introduction 
Periodontal disease is a major oral health problem. It is 
characterized by severe inflammation with loss of the supporting 
structures and the attachment apparatus.[1] In periodontitis, the 
production of proinflammatory cytokines and tissue-degradative 
enzymes is initiated and advanced by oral bacterial infection, 
ultimately resulting in the destruction of periodontal tissue.[2] 
Over the years, various treatment modalities have been tried with 
varying success to correct periodontal attachment and alveolar 
bone loss resulting from this disease.[1] Therapy has been aimed 
primarily at reduction of etiologic factors to reduce or eliminate 
inflammation, thereby allowing gingival tissues to heal. 
Therapeutic approaches for periodontitis falls into two major 
categories: 1) anti-infective treatment, which is designed to halt 
the progression of periodontal attachment loss by removing 
etiologic factors; and 2) regenerative therapy, which includes anti-
infective treatment and is intended to restore structures destroyed 
by disease [3]. 
Nonsurgical periodontal therapy includes both mechanical and 
chemotherapeutic approaches to minimize or eliminate microbial 
biofilm (bacterial plaque), the primary etiology of gingivitis and 
periodontitis.[4] 
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Various methods employed are [5] 
Mechanical non-surgical therapy 
Hand instrumentation 
Sonic/ ultrasonic instrumentation 
Reciprocating instruments 
Ablative laser therapy 
Chemotherapeutic agents 
 
Antibacterial agents have been used widely in the management of 
periodontal infection. The effectiveness of mechanical 
debridement and repeated topical and systemic administration of 
antibacterial agents are limited due to the lack of accessibility to 
periodontopathic organisms in the periodontal pocket. Systemic 
administration of drugs leads to therapeutic concentrations at the 
site of infection, but for short periods of time, forcing repeated 
dosing for longer periods [6]. 
The use of local delivery of antibacterial agents to sites of active 
periodontitis has aroused considerable interest because of the 
possibility of achieving a maximum antibacterial concentration 
with minimal side effects. The concept of local drug delivery was 
championed by Dr Max Goodson in the year 1979 [7].The concept 
that local drug delivery of an antibiotic into the periodontal pocket 
achieves a greater, more potent concentration of drug than 
available with systemic delivery is very appealing.  The amount of 
drug delivered often creates sulcular medication concentrations 
exceeding the equivalent of 1mg /ml. This level is considered 
bactericidal for the majority of bacteria that exhibit resistance to 
systemically delivered concentrations. Local application into 
periodontal pocket could be very advantageous, both in terms of 
increasing drug concentration directly in the action site, and in 
preventing systemic side effects such as gastrointestinal 
complaints, depression, and tachycardia [3]. 
Sustained or controlled releasing local delivery antimicrobial 
agents (LDAs) are available for use as adjuncts to scaling and 
root planning (SRP) in the treatment of periodontitis. These 
products are placed into periodontal pockets in order to reduce 
subgingival bacterial flora and clinical signs of periodontitis.  
Simvastatin is a hypolipidemic drug belonging to the class of 
pharmaceuticals called "statins". It is used to control 
hypercholesterolemia (elevated cholesterol levels) and to prevent 
cardiovascular disease. Simvastatin is a synthetic derivate of a 
fermentation product of Aspergillus terreus [8] marketed under the 
trade names Zocor, Simlup, Simcard, Simvacor, and others, as 
well as generically. 
Statins like simvastatin (SMV), lovastatin, and pravastatin are 
specific competitive inhibitors of 3-hydroxy-2-methyl-glutaryl 
coenzyme A (HMGCoA) reductase.[9-11] Statins also seem to 
modulate bone formation by increasing the expression of bone 
morphogenetic protein-2, inflammation, and angiogenesis[12], 
thus providing a new direction in the field of periodontal 
therapy.[1] 
Various animal studies [13-15] have shown that SMV assists in 
bone regeneration and produces an anti-inflammatory effect when 
delivered or applied locally. It has shown to stimulate bone 
formation when injected subcutaneously over the murine calvaria 
and also increased expression of BMP-2 mRNA in 
osteoblasts.[16,17] In-vitro studies[18,19] and clinical 
studies[12,20-22]  confirmed its positive effect on bone formation 
and focused on bone diseases, especially osteoporosis. It also 
showed decrease production of IL-6 and IL-8, an effect that was 
reversed by adding mevalonate or geranylgeranyl pyrophosphate 
but not farnesyl pyrophosphate.[14,23,24] This side effect of 
statins could be of interest in the regeneration of periodontal 
defects, especially hard tissue regeneration.[25] 
SMV reduced nuclear factor-kappa B and activator protein 1 
promoter activity in KB cells, indicating an anti-inflammatory effect 
of SMV on human oral epithelial cells, apparently involving Rac1 
GTPase (a hydrolase enzyme that can bind and hydrolyze 
guanosine triphosphate) inhibition.[14] 
Simvastatin is indigenously prepared using methylcellulose and 
double distilled water in sterile conditions and inserted into the 
disease sites using a blunt cannula carrier. Periodontal therapy is 
aimed at the restoration of tissues destroyed by disease. 
However, achieving greater predictability with regenerative 
therapy requires the introduction of an agent which not only 
hampers tissue destruction but also enhances the regenerative 
capabilities of the periodontal tissues. 
The aim of this study was to assess the clinical and radiographic 
effects of 1.2% Simvastatin in-situ gel as an adjunct to scaling and 
root planing in the treatment of chronic periodontitis. 
Materials and Methods 
60 sites were selected with minimum one intrabony defect in any 
quadrant and probing pocket depth of >5mm in both male and 
female subjects (33 males and 27 females), aged 25 to 45 years, 
who were diagnosed with chronic periodontitis from May 2010 to 
June 2011.  The study sample was selected from the patient pool 
of the Department of Periodontology, Meenakshi Ammal Dental 
College, Chennai, with approval from the ethical committee of 
MAHER university of Chennai, and followed the Declarations of 
Helsinki.[26] The inclusion criteria were patients who were 
systemically healthy with generalized chronic periodontitis with 
probing pocket depth (PPD) >5mm and radiographic evidence of 
vertical bone loss º3mm in atleast 1site and those with the ability 
to maintain optimum oral hygiene after the initial phase of 
treatment. Those with known or suspected allergy to SMV, on 
systemic statin therapy, patients with aggressive periodontitis, 
smokers and history of antibiotic or periodontal therapy in 
preceding 6 months were excluded from this study. 
 They were divided into 2 groups randomly by using coin toss 
method and patients were assigned to two groups by the clinician: 
 
Group A (Control): 30 sites were treated with SRP and placebo  
Group B (Test): 30 sites were treated with SRP and Simvastatin 
(SMV) gel 
 
All the subjects, selected in this study received supragingival 
scaling and were given oral hygiene instruction prior to the 
commencement of the study. Customized stents were prepared 
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for the sites where the drug was to be administered for 
standardisation of the parameters throughout the course of the 
study. The parameters such as plaque index (PI),Modified sulcus 
bleeding index (mSBI), Probing pocket depth (PPD),Clinical 
attachment level (CAL), Radiographic assessment of intrabony 
defect (IBD) and level of interleukin-6 mRNA levels in the sulcular 
epithelium of the test site before and after the drug delivery (IL-6-
mRNA) were recorded at different time points during the course of 
the study. 
The PI, mSBI, PPD and CAL was assessed at baseline (0 day) 
before SRP and placebo in Group A and prior to SRP and local 
delivery of simvastatin in Group B (Fig .I) and again at 60th day, 
90th day and 180th day. The radiographic assessment of IBD was 
done for both Group A and Group B at baseline (0 day) and 180th 
day by computer aided software.IL-6-mRNA levels were 
determined at baseline and 90 days after drug delivery using PCR 
analysis. 
Radiographic Analysis of Intrabony Defects [27] 
Individually customized bite blocks and a parallel-angle technique 
were used to obtain standardized films. All radiographs were 
reviewed in a single reference center by a masked evaluator. For 
evaluation, radiographs were scanned at 800 dots per inch with a 
scanner, and IBD was evaluated using computer-aided software 
(Coral Draw, Version X5). IBD was measured on the radiograph 
by measuring the vertical distance from the crest of the alveolar 
bone to the base of the defect. 
Preparation of 1.2% Simvastatin Gel [28] 
The constituents of simvastatin containing gel were simvastatin 
(10 or 20 mg) tablets, carboymethylcellulose, and double distilled 
water. This mixture was prepared using 4% (w/v) methylcellulose 
gel, which served as a vehicle for the drug. The above mentioned 
volume of the vehicle was obtained by adding 100ml of hot double 
distilled water to 4g of methylcellulose powder at 500C. 1.2g of 
simvastatin was then added to the homogenous phase of 
polymer. The vial was heated between 500C-600C and agitated 
using a mechanical shaker to obtain a clear solution. The gel was 
prepared at a concentration of 1.2%. 
Local Drug Delivery 
Thorough scaling and root planing was done for both the groups 
and the areas were properly irrigated with physiologic saline.  For 
standardization, 0.1 ml prepared SMV gel (1.2 mg/0.1 ml) was 
injected into the periodontal pockets in Group B using a syringe 
with a blunt cannula. No periodontal dressing was applied after 
delivery of the drug because the prepared formulation decreases 
in viscosity, which causes swelling and occlusion of the 
periodontal pocket. 
After placement of the in situ gel, patients were instructed to 
refrain from chewing hard or sticky foods, brushing near the 
treated areas, or using any interdental aids for 1 week. Adverse 
effects were noted at recall visits, and any supragingival deposits 
were removed. 
Measurement of IL-6-mRNA 
 
Subgingival epithelial samples were collected with a sterile 
Gracey curette from the (preselected) deepest site in each 
quadrant (Fig.II). These samples were collected from the sites 
prior to treatment  and 90 days following treatment in the Test 
group (Group B).Assessment of IL-6 level was carried out by PCR 
(Peq star universal gradient Thermocycler). After collecting the 
subgingival epithelial samples, it was transferred into 2ml 
ependroff tube containing 1ml of physiological saline (Fig.III) and 
kept in a freezer at -20◦C. Then the DNA samples were isolated 
from the samples. 
Isolation of the genomic DNA 
This procedure was carried out as per the protocol given by the 
manufacturer. The DNA templates were stored at î20ĈC until 
further use. 
 
Primers: Forward (Fwd) FOR IL -6 :  (Euro f ins )  
Forward primer design: TTGTCAAGACATGCCAAA 
Reverse primer design: TCAGACATCTCCAGTCCT 
 
17øl of master mix was mixed with 2øl of each of forward and 
reverse primers and 1øl of template DNA and the reaction mixture 
was loaded in the PCR machine and programmed. 
10øl of PCR amplified samples was mixed with 1øl of dye and 
loaded into the gel.  Electrophoresis was run at 50 to 100v till the 
tracking dye reached 2/3rd of the distance of gel length and gel 
was then visualized in gel documentation. 
Detection and analysis of the reagent product 
The amplified strands were observed and compared with DNA 
ladder (with the known molecular weight) to find out the base pair 
of the unknown DNA. 
Statistical Analysis 
Mean and standard deviation were estimated from the sample for 
each experimental site. Mean changes were compared against 
the null hypothesis. StudentÊs paired t-test was employed to test 
the significance of mean differences between 0-day, 60th day, 90th 
day and 180th day. One way-ANOVA was employed to calculate 
the mean differences within the groups. Chi-square test was 
employed to calculate the IL-6-mRNA levels in the test group at 0-
day and 90th day. 
For all the tests, a p-value of 0.05 or less was considered for 
statistical significance. 
Results 
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60 patients completed the study. Sixty treatment sites (one site/ 
subject) were evaluated for clinical parameters at baseline (before 
SRP) and at 60th, 90th and 180th day; radiographic parameters 
were recorded at baseline and at 180th day in 60 treatment sites 
by the assistant who did not know which group was being 
assessed as it was not told. IL-6-mRNA levels were evaluated for 
the test group before and after the drug delivery at 0-day and 90th 
day. 
Clinical evaluation 
No adverse reaction was observed in any subject from the test 
group and no discomfort was reported. All subjects tolerated the 
drug well without any post-application complications. 
Evaluation of oral hygiene 
No statistically significant differences were found between group 
A and group B at any time point except 180th day for site-specific 
plaque scores. This indicates that both groups maintained 
comparable levels of oral hygiene throughout the study. (Table I) 
mSBI 
A statistically significant decrease in mSBI scores from baseline 
was found in both groups. The decrease in mSBI score was 
greater in group B at 90th and 180th day (2.5μ0.6) compared to 
group A (1.9μ0.9) (p< 0.05). (Table II and III). 
PD 
Statistically significant decrease in PD was found in both groups 
at the end of the study. When both the groups were compared the 
decrease in PD was greater in group B at all the time points 
compared to group A (p< 0.05) (Table II and III). 
CAL 
The difference from baseline was statistically significant within the 
groups in CAL gain (Fig.IV), but when compared there was no 
significant difference between the groups. (Table II and III). 
IBD Fill 
There was greater decrease in mean IBD in group B (Fig.Va, Fig 
Vb) compared to group A (p< 0.02). Both the groups showed 
significant decrease from baseline to 180th day. (Table IV) 
Analysis of IL6--mRNA levels in sulcular epithelium 
The chi-square value for IL-6 level in group B at 0th day (Fig.VIa) 
and 90th day (Fig.VIb) was 42, which was statistically significant 
(p-value-0.0001) and showed a significant decrease following the 
application of the drug. (Fig.6C) 
Discussion 
Nonsurgical mechanical periodontal treatment is the cornerstone 
of periodontal therapy and the first recommended approach to the 
control of periodontal infections.[29] Although nonsurgical 
periodontal therapy has evolved over the years, it is still 
considered to be the gold standard to which other treatment 
methods are compared.  
A strategy against biofilm infection has been proposed recently in 
which the dental plaque community is disrupted by targeting the 
easy-to-remove key members, leaving a biofilm community which 
cannot support pathogenic species. However, a wealth of 
evidence shows that conventional mechanical debridement 
cannot eradicate all periodontopathic bacteria from the 
subgingival environment, especially those inhabiting inaccessible 
areas such as furcations, grooves, concavities and deep 
pockets.[6]  
Advances in understanding the etiology and pathogenesis have 
led to the development and subsequent acceptance of the use of 
pharmacological agents in the management of periodontal 
diseases. Local drug delivery systems have the ability to deliver 
the antimicrobial agents to the target sites, achieve a sufficient 
concentration, and last for a sufficient duration to be 
effective.3The clinicianÊs decision to use LDAs should be based 
upon a consideration of clinical findings, the patientÊs dental and 
medical history, scientific evidence, patient preferences, and 
advantages and disadvantages of alternative therapies.[30] 
Advantages of using the subgingival drug-delivery system include 
achieving high intrasulcular drug concentrations, avoiding its 
systemic side effects, and better patient compliance.3 The non-
surgical therapy has covered a new dimension by addition of yet 
another newer drug, Simvastatin, to the family of local drugs.  
The purpose of this study was to determine whether non-surgical 
intrasulcular placement of simvastatin in methylcellulose gel can 
augment bone in human intrabony defects. Such a non-surgical 
approach is unconventional but, if successful, would provide a 
flexible and economical means of adding bone in periodontal 
therapy. Critical to this approach was thorough defect 
debridement involving the removal of all granulation tissue in the 
defect. 
In this study simvastatin was used in gel form with 
carboxymethylcellulose as the vehicle. Researchers have found 
out that the gels composed of cellulose derivatives such as 
hydroxypropylmethyl cellulose and hydroxyethyl cellulose do not 
appear to have the property of sustained release. Surprisingly, 
despite the rapid drug release and poor retention of these gels, 
positive clinical results in moderate to deep periodontitis were 
obtained.[3] 
Both the groups maintained comparable levels of oral hygiene 
throughout the study. In the present study there was decrease in 
the plaque scores in both groups from baseline to 6 months, 
where Group A showed a decrease from 2.2μ0.5 to 0.7μ0.5 and 
Group B showed a mean decrease from 2.0μ0.6 to 0.3μ0.4. There 
was a significant difference in plaque scores between the two 
groups only at 6 months (p-value <0.005) showing a greater 
reduction in the test group. The results were similar to studies 
done by Pradeep et al [20] that showed comparatively greater 
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plaque reduction with locally administered simvastatin gel and 
Martha et al [31] who used systemic atorvastatin in a pilot study in 
chronic periodontititis patients however this could be due to 
increased patientÊs awareness of the treatment and hence better 
maintenance by the test group under study. 
The other effects of this drug on the study group were as follows: 
Effect on gingival bleeding scores 
In  the present study we observed a significant reduction in 
gingival bleeding index scores for both the groups from baseline 
to 6 months, where Group A (control) showed a decrease from 
2.6μ0.5 to 0.7μ0.7(p<0.001) and Group B (test) from 2.7μ0.4 to 
0.2μ0.4(p<0.001). On comparison of both groups, statistically 
significant reduction of mSBI was observed in Group B (p<0.005) 
which suggests an anti-inflammatory effect of SMV. A similar anti-
inflammatory effect of SMV was observed by Lindy et al in 2008 
[32] using systemic statin therapy in patients with chronic 
periodontitis. 
The soft tissue wall changes due to resolution of gingival 
inflammation explain the improvement in clinical parameters in 
this study. The magnitude of the changes is related to the initial 
pocket depth, tooth type, and other environmental factors.[29] 
Effect on PD and CAL 
A decrease in probing depth and gain in CAL are the major 
clinical outcomes measured to determine the success of any 
periodontal treatment.  
A significant decrease in PD was seen in both the groups at the 
end of the study, where Group A (control) showed a decrease 
from 6.6μ1.5mm to 4.5μ1.7mm and Group B (test) from 
6.3μ1.7mm to 2.3μ0.6mm by the end of 6 months.When 
comparing the two groups, the decrease in PD was statistically 
significant at each time point, even after 6 months (p<0.001). 
Group B showed a greater reduction in pocket depth of 4.0μ1.6 
(p<0.00) as compared to the control group of 2.1μ0.8 by the end 
of 6 months. Yazawa et al [33] studied the effect of SMV on 
human periodontal (PDL) cells in vitro and showed that at a low 
concentration SMV exhibits a positive effect on the proliferation 
and osteoblastic differentiation of human PDL cells, and these 
effects may be caused by inhibition of the melvalonate pathway 
thereby leading to periodontal regeneration.  
Gain in CAL was seen in both the groups at the end of the study, 
where Group A showed a gain from 7.4μ1.0 to 5.1μ1.2 and Group 
B showed a gain from 7.5μ1.6 to 2.8μ1.2.When comparing the 
two groups, the gain in CAL was statistically significant at all time 
intervals, even after 6 months (p <0.001) within both the groups. 
Group B showed a greater gain in CAL at 2 months (p<0.049), 3 
months and 6 months. (p < 0.001) . Similar results were observed 
by Pradeep et al [20] showing a significant decrease in PD and 
gain in CAL in patients who were treated with subgingivally 
delivered simvastatin gel. 
Effect on Bone regeneration 
Although clinical changes in the periodontal pocket have been 
extensively researched, the osseous changes following 
nonsurgical periodontal therapy have received less attention. 
Previous studies [4,6] have shown that intraosseous defects 
treated with nonsurgical periodontal therapy resulted in an 
increase in radiographic bone levels of 0.2 mm at 6 months, 0.3 
mm at 12 months and 0.5 mm at 24 months after therapy. 
This study confirms that local simvastatin upregulates bone 
growth. Simvastatin was chosen as the statin to be tested in the 
in-vivo study as in vitro studies have shown it to be among the 
most potent in stimulating bone growth and other predictors of 
osteoinduction.12,35 The impact of simvastatin on bone 
metabolism therefore would appear to involve a complex 
interaction with cholesterol metabolites, growth factors, 
inflammatory cytokines and hormones.[13] 
In the present study, there was a greater decrease in IBD for 
Group B of 0.57μ1.0 as compared to Group A of 0.08μ0.1 but the 
comparison was not significant at any of the time point. There was 
a significant reduction within the groups for Group A (p<0.006) 
and Group B (p<0.007) which was greater for the group with SMV 
(p<0.02). These observations were similar to that of Pradeep et al 
[21] who also showed a 32.5% decrease in mean IBD in chronic 
periodontitits patients with locally administered simvastatin gel 
and 2.16% in those treated with SRP alone. 
Morris et al [12] studied the effect of injectable SMV in three-
walled periodontal IBDs, Class II furcations defects, and 
edentulous alveolar ridges in beagle dogs by histomorphometric 
analysis; 29% greater ridge thickness was found with SMV, but 
bone height loss was detected in the interproximal intrabony and 
furcation defects. However, the present study showed effective 
IBD fill and a greater decrease in PD and CAL gain compared to 
the control group. 
The possible errors in measuring the IBD fill on radiographs, such 
as those due to exposure settings, geometric error (e.g. 
radiographic techniques), and the development of films, were 
minimized by using a standardized paralleling technique.  
Effect on Interleukin-6-mRNA levels 
The PCR analysis was used to evaluate the IL-6 levels from the 
sulcular epithelial cells of the periodontal pocket. IL-6 increases in 
the sites of gingival inflammation and plays a role in bone 
resorption via induction of RANKL. It also stimulates the 
osteoclast formation and activity [24]. 
In the current study the mean decrease in IL-6 level from 0 day to 
90th day for Group B was statistically significant (p-value-
0.0001).IL-6 was present only in 4 samples out of 30 by the end of 
90th day after the placement of SMV. In this study, we are one of 
the few to prove that simvastatin reduces IL-1đ induced production 
of inflammatory cytokines such as IL-6 by human oral epithelial 
cells. Ikeda and Shimada in 1999 [35] studied the effects of 
statins on the production of interleukin-6 by cultured human 
monocytes and smooth muscle cells. 
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The addition of statins significantly decreased IL-6 production by 
these cells. Thus, claiming their biologically significant anti-
inflammatory effect which could prove beneficial in the treatment 
of periodontitits. Sakoda et al [14] also showed anti-inflammatory 
effect of SMV on human epithelial cells, apparently involving Rac1 
GTPase inhibition, and found decreased IL-6 and IL-8 
productions. They also confirmed inhibition of IL-8, IL-10, IL-12, 
and TNFđ production. [24] Michihiko et al [36] in 2008 showed that 
simvastatin decreased the expression of these inflammatory 
cytokines and promoted activity of downstream pathway which 
could also explain its anti-inflammatory effects on the bleeding 
scores. 
With the current availability of number of intra-pocket delivery 
systems containing antimicrobials for periodontal therapy, 
questions can be raised about the efficacy of these delivery 
devices in periodontal regeneration.3 The findings of this study 
involving simvastatin as a local drug delivery system has been 
encouraging as its effects on bone metabolism favours its use in 
the treatment of periodontal defects. Limitations of the study have 
been that of a proper control for IL-6 level analysis and its 
quantitative analysis and need for longer follow up period yet even 
then it has tried to overcome the shortcomings of previously used 
devices and was relevant in the present study as it provided with 
significant reduction in periodontal inflammatory damage in the 
test group. 
Conclusion 
These observations may give new direction in the field of 
periodontal regeneration, to achieve the goal of regeneration 
without any invasive procedures, thereby causing less discomfort 
to the patients. However, long-term studies, using different 
vehicles and concentrations of SMV, should be carried out to 
affirm the observations of our study. 
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Table 1. Comparison of mean values for PI (Plaque Index) scores for Group A and Group B at different time points. 
 
Plaque Index 0th day 60th day 90th day 180th day 
Grp A Grp B Grp A Grp B Grp A Grp B Grp A Grp B 
 2.2±0.5       2.0±0.6 1.0±0.5     
0.8±0.4 
0.8±0.6     
0.4±0.6 
0.7±0.5     
0.3±0.4 
P value 0.21 (N.S.) 0.19 (N.S.) 0.051 (N.S) 0.005 (Sig.) 
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Table II. PD, CAL, and mSBI for Groups A and B (mean ă SD) at Different Time Intervals 
     Groups     Timepoint        PD (mm)        CAL(mm) Sulcus Bleeding Index (mSBI) 
         A         0th Day 6.6±1.5 7.4±1.0 2.6±0.5 
         60th Day 5.5±1.5 6.0±1.2 1.0±0.6 
         90th Day 4.8±1.5 5.4±1.2 0.8±0.8 
        180th Day 4.5±1.7 5.1±1.2 0.7±0.7 
         B          0th Day 6.3±1.7 7.5±1.6 2.7±0.4 
         60th Day 4.4±1.6 5.2±1.7 0.7±0.6 
         90th Day 3.2±1.2 3.8±1.4 0.2±0.4 
        180th Day 2.3±0.6 2.8±1.2 0.2±0.4 
 
 
 
Table III: Decrease in PD,CAL Gain and Gingival Index (mSBI) From Baseline (mean – SD) at Different Time Intervals for 
Groups A and B 
 
Parameters Timepoint Group A Group B P value 
PD         60th Day 1.1±0.5 1.9±1.7 0.02(Sig.) 
         90th Day 1.8±0.7 3.1±1.5 0.00(Sig.) 
        180th Day 2.1±0.8 4.0±1.6 0.00(Sig.) 
CAL         60th Day 2.2±1.5 2.2±1.5 1.00(N.S.) 
         90th Day 3.6±1.6 3.6±1.6 1.00(N.S.) 
        180th Day 4.6±1.5 4.6±1.5 1.00(N.S.) 
mSBI         60th Day 1.5±0.7 2.0±0.9 0.052(N.S.) 
         90th Day 1.8±0.9 2.5±0.6 0.002(Sig.) 
        180th Day 1.9±0.9 2.5±0.6 0.005(Sig.) 
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Table IV: Comparison of IBD Values From Baseline to 6 Months 
Group 
 
Time  
 
IBD  
(mm; mean – SD) 
 
IBD Decrease 
(mm; mean – SD) 
P value Intergroup 
P value 
A 0t h  Day 
180t h Day 
7.3±1.1 
7.2±1.0 
0.08±0.1 0.006(Sig.)  
0.02 (Sig.) 
B 0t h  Day 
180t h Day 
7.2±1.2 
6.6±1.3 
0.57±1.0 0.007(Sig.) 
 
 
 
Flowchart summarizing the parallel study design 
 
 
Total pts. n=60
(33 males and  27 females)
Group A (n=30)
(18 males and 12 females)
SRP + placebo
Results were assessed at 
baseline, 60th. 90th, 180th 
day
IL‐6‐mRNA levels were 
assessed at baseline and 
90th day
Group B (n=30)
(15 males and 15 feamles)
SRP + SMV
Results were assessed at 
baseline, 60th. 90th, 180th 
day
IL‐6‐mRNA levels were 
assessed at baseline and 
90th day
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